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The transcription factors c-Myc and Mnt regulate gene expression through dimerization with Max
and binding to E-boxes in target genes. While c-Myc activates gene expression via recruitment of
histone modifying complexes, Mnt acts as a transcriptional repressor. Here, we used the Xenopus
leavis oocyte system to address the effect of c-Myc and Mnt on transcription and chromatin
remodeling over the E-box region in the human telomerase reverse transcriptase (hTERT) promoter.
As expected we found elevated and decreased levels of hTERT transcription upon exogenously
expressed c-Myc/Max and Mnt/Max, respectively. In addition, we conﬁrmed binding of these
heterodimers to both E-boxes already enriched with H3K9ac and H4K16ac. These chromatin marks
were further enhanced upon c-Myc/Max binding followed by increased DNA accessibility in the E-
box region. In contrast, Mnt/Max inhibited Myc-induced transcription and mediated repression
through complete chromatin condensation and deacetylation of H3K9 and H4K16 across the E-box
region. Importantly, Mnt was able to counteract c-Myc mediated activation evenwhen expressed at
low levels, suggesting Mnt to act as a strong repressor by closing the chromatin structure.
Collectively our data demonstrate that the balance between c-Myc and Mnt activity determines the
transcriptional outcome of the hTERT promoter by modulation of the chromatin architecture.
& 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
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dimers with Max [2]. c-Myc/Max complexes bind preferentially to
promoters enriched for euchromatin marks such as H3K4me2,
H3K4me3, H3K79me2, H3K9ac, H3K18ac and H3K27ac [3–6]. In
addition, Myc was found in genomic regions containing CpG
islands, which generally are associated with transcriptionally
active promoters [7]. Myc was recently shown to accumulate in
the promoter regions of active genes where it acts as an ampliﬁer
of expression rather than being an on-off speciﬁer of gene activity
[5,6]. However, the on-off switch might be controlled by c-Myc
indirectly since c-Myc interacts with 10–15% of human promoters
(reviewed in [8]).
The accessibility of the chromatin is crucial for gene expression.
Nucleosomes, consisting of DNA wrapped around the histone
octamer (histone H3, H4, H2A and H2B), are packed into higher
order chromatin structures restricting protein binding to DNA.
Thus, local modulation of DNA accessibility inﬂuences the tran-
scriptional outcome [9]. Once c-Myc/Max is bound to the promoter
additional histone modiﬁcations are induced by recruitment of
various cofactors including histone acetyltransferases (HATs) Tip60
[10], GCN5/PCAF [11,12] and p300/CBP [13], HAT associated pro-
teins such as Transactivation/transformation domain associated
protein (TRRAP) [11,14], members of the SWI/SNF chromatin
remodeling complex (SNF5 and BRG1) (reviewed in [15–17]),
histone methyltransferase mixed-lineage leukaemia 1 (MLL1) [18]
and ATPase/helicase TIP48 and TIP49 ([19,20].
Myc induced transactivation is antagonized by binding of Mxd/
Max or Mnt/Max heterodimers to the same E-box sequence
resulting in establishment of an inactive chromatin conformation
through recruitment of mSin3 containing corepressor complexes
possessing histone deacetylase (HDAC) activity [21,22]. HDACs
remove acetyl groups from histones, leading to decreased histone
acetylation, chromatin condensation and, hence, transcriptional
repression [23].
We have previously analyzed the promoter of the c-Myc/Mxd/
Mnt target gene human telomerase reverse transcriptase (hTERT),
and found a switch from c-Myc/Max to Mad1(Mdx1)/Max bind-
ing during differentiation of human promyelocytic leukemia
(HL60) cells resulting in decreased promoter histone acetylation
followed by reduced hTERT expression [24]. In contrast to c-Myc
and Mxd, which are expressed in proliferating and differentiating
cells, respectively, Mnt is ubiquitously expressed and Mnt/Max
complexes are present at the promoter during both cellular
stages [24,25]. However, we found that Mnt mediated transcrip-
tional repression is inhibited through phosphorylation of the
protein in proliferating cells [25]. Furthermore, since Mnt has
been suggested as a key regulator of the Myc network as well as
a potential tumor suppressor (reviewed in [26]) we wanted to
study how c-Myc and Mnt regulate gene expression by remodel-
ing of the chromatin structure across the E-box region in the
hTERT promoter. To this end, we reconstituted the promoter in
the Xenopus leavis oocyte system [27]. Oocytes from the African
clawed frog are large cells allowing cytoplasmic microinjection
of in vitro synthesized c-Myc, Max or Mnt mRNA(s) and nuclear
injection of the corresponding expression vector(s) [28]. Repor-
ter DNA containing the hTERT promoter is provided by injection
into the oocyte nucleus where it undergoes chromatin assembly
within a few hours. In this way, the interaction between newly
assembled chromatin of the hTERT promoter and c-Myc/Max or
Mnt/Max as well as chromatin dynamics during transcriptionalactivation/repression by c-Myc and Mnt can be analyzed at high
precision.Materials and methods
Ethics statement
Ethic permissions N61/09, #C10/10 and N21/12 were approved by
the Stockholm regional ethical committee for animal research.Xenopus oocyte microinjection and plasmids
Defolliculated stage VI Xenopus laevis oocytes were prepared by
collagenase treatment [29]; microinjections of DNA and mRNA into
the oocytes were performed as described previously [30]. The c-Myc,
Max, Mnt cDNAs were cloned between the BamH1/Not I sites in the
RN3P vector, used for mRNA production as described [31]. The
plasmids were linearized with Acc651 and in vitro transcribed
using the mMESSAGE mMACHINE kit (Ambion). Obtained mRNAs
were puriﬁed on a spin column (MEGAclear, Ambion). Indicated
amount of c-Myc, Max or Mnt mRNA were injected in 23 nl into
the cytoplasm. 5 to 7 h after mRNA injection, 3 ng single stranded
(ssDNA) or double stranded (dsDNA) of the hTERT promoter
plasmids hTERT A (p1009, [32]), hTERT B (p330, [32]), hTERT C
(pBT-255, [33]), or minM4tkLuc [34] in 18.4 nl were injected into the
oocyte nucleus. For expression of the hTERT containing reporters as
ssDNA, 1009/+360 bp fragment (hTERT A) or 330/+360 bp frag-
ment (hTERT B) were cloned into M13-mp19 bacteriophage vector
using KpnI and SacI. For some experiments DNA expression vectors
for c-Myc (pSp-Myc), Max (pSp-Max), Mnt (pRc-Mnt1A) were used
to express the corresponding protein. In this case the plasmids were
co-injected into the nucleus together with the hTERT or minM4tkLuc
reporter. Injected oocytes were incubated in OR2 medium (82.5 mM
NaCl, 2.5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM Na2HPO4, 5 mM
HEPES pH 7.8) containing 10 μg/ml gentamicin (Sigma-Aldrich) at
19 1C for 24 h before analysis (Fig. SI1A). Pools of 7–10 injected
oocytes of each group were used and all experiments were performed
in duplicates or triplicates.Analysis of intracellular amounts of exogenously expressed
proteins
Xenopus oocytes injected with c-Myc,Max,MntmRNA, or expression
vectors for Mnt or Max were incubated in OR2 medium containing
14C-Lysine. 24 h post injection the oocyte nuclei were manually
dissected in nuclear isolation buffer (20 mM Tris–HCl pH 7.5,
0.5 mM MgSO4, 140 mM KCl) and homogenized in 10 mM Tris–HCl
pH 7.5 containing complete protease inhibitor cocktail (Roche).
Protein extracts were separated in 8 or 10% SDS PAGE followed by
Western blot or by autoradiography of the dried gels. Western
blotting was performed as previously described [35]. Membranes
were probed with anti-c-Myc antibody (N262), anti-Max (C17) or
anti-Mnt (M132), all from Santa Cruz Biotechnology Inc, or anti-actin
(A2103) from Sigma. HRP-conjugated anti-rabbit antibody (Amer-
sham Biosciences) was used as secondary antibody. Membranes
were developed by enhanced chemiluminescence (ECL, Amersham).
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Human embryonic kidney (HEK293T) cells were cultured in
Dulbecco′s Modiﬁed Eagle Medium (DMEM) medium supplemented
with 10% FBS and 1% Glutamine. Cells were transiently transfected
using Lipofectamine 2000 (Invitrogen) according to the manu-
facturer′s instructions.Luciferase reporter assay
Xenopus oocytes were microinjected with c-Myc, Max or Mnt mRNA
or with Max and Mnt expression vectors together with the hTERT
promoter DNA (hTERT A, B or C) or minM4tkLuc. HEK293T cells were
transiently transfected with pSp-Myc, pSp-Max, pSp-vector, pRc-
Mnt1A or pRc-vector together with hTERT promoter (hTERT A, B or C)
or minM4tkLuc DNA. All transfections included pCMV-β-galactosi-
dase as control for transfection efﬁciencies. Twenty-four hours post
transfection or oocyte injection, cells were lysed in extraction buffer
(25 mM Tris pH 7.8, 2 mM EDTA, 2 mM DTT, 10% glycerol, 1% Triton
X-100) and analyzed for luciferase activity in Analysis buffer (25 mM
Glycylglycin, 15 mMMgSO4, 5 mM ATP) containing 0.2 mM Luciferin
using a luminometer. Luciferase activity in cells was normalized for
differences in β-galactosidase levels in Z buffer (60 mM Na2HPO4,
40 mM NaH2PO4, 10 mM KCl, 1 mMMgSO4, 50 mM β-mercaptoetha-
nol) containing 0.8 μg/μl ortho-nitrophenyl-β-galoctidase (ONPG).
After incubation at 37 1C for appropriate time 0.3 M of NaCO3 was
added and the β-galactosidase levels were measured in an ELISA
reader at 420 nm.Chromatin immunoprecipitation (ChIP)
Pools of ten oocytes were microinjected with c-Myc/Max orMnt/Max
mRNA and hTERT A promoter DNA 24 h prior to crosslinking with 1%
(v/v) formaldehyde for 10 min at ambient temperature. Next,
oocytes were homogenized in 10 mM Tris–HCl pH 7.2, 0.1% SDS
and complete protease inhibitor cocktail (Roche). Chromatin equiva-
lent to 1 oocyte was used for immunoprecipitation in buffer I (0.1%
Na-deoxycholate, 1% Triton-X-100, 2 mM EDTA, 50 mM Hepes
pH 7.2, 150 mM NaCl, 1 mM DTT, protease inhibitor cocktail (Roche))
with the following antibodies; c-Myc (N262), Max (C17), Mnt
(M132), normal rabbit IgG control (all four from Santa Cruz
Biotechnologies Inc.), AcH3K9 (#07-352) and AcH4K16 (#07-329)
(both from Upstate/Millipore). To collect protein-chromatin com-
plexes, salmon sperm DNA coated protein G agarose beads (Upstate/
Millipore) were used. The complexes were washed with Buffer I,
Buffer II (0.1% Na-deoxycholate, 1% Triton-X-100, 2 mM EDTA,
50 mM Hepes pH 7.2, 500 mM NaCl, 1 mM DTT, protease inhibitor
cocktail (Roche)), Buffer III (0.25 M LiCl, 0.5% Na-deoxycholate, 1 mM
EDTA, 10 mM Tris–HCl pH 8, 1 mM DTT, protease inhibitor cocktail
(Roche)) and TE. After elution in 0.5% SDS, 0.1 M NaHCO3, 0.5 μg/μl
proteinase K, the protein-chromatin complexes were reverse-
crosslinked at 65 1C overnight. As input, total chromatin was used.
The DNA was puriﬁed by PCR puriﬁcation kit (Qiagen) and analyzed
by PCR using the following primers: vector: (5′-TCCGTGGTG-
TCTTTGCGTTTC-3′; 5′-TGGCATGATTAAGACTCCTTATTACGC-3′), hTERT
5′ E-box: (5′-CCTTCACGTCCGGCATTCGTGG-3′; 5′-ACCCGTCCTG-
CCCCTTCACCTT-3′), hTERT 3′E-box: (5′-ACCCGTCCTGCCCCTTCACCT-
3′; 5′-CAGCACCTCGCGGTAGTGGCT-3′).DMS methylation protection assay and primer extension
DMS methylation protection assay was performed as described
previously [27]. In brief, pools of 10 oocytes were treated with
DMS in 500 μl OR2 medium containing 1.5 μl of DMS for 10 min at
room temperature. After washing in OR2 solution oocytes were
homogenized and treated overnight with proteinase K (100 μg/
ml) in 1% SDS and 10 mM EDTA. After DNA puriﬁcation the
methylation pattern was developed by primer extension using
Deep vent (exo-) polymerase (New England Biolabs) and [33P]-
labeled primer (5′-AGCACCTCGCGGTAGTGGCT-3′) as described
previously [27]. Products of linear ampliﬁcation were separated
in 6% denaturing PAGE followed by analysis of dried gel with Fuji
Bio-imaging analyzer BAS-2500 using Image Gauge V3.3 software.
DNase I hypersensitivity assay
Oocytes injected with hTERT A or B promoter DNA and c-Myc/Max
or Mnt/Max RNA or DNA expression vectors was digested with
DNase I as described previously [30]. In brief, pools of twenty
oocytes were homogenized using Dounce homogenizer in 10 mM
Tris–Cl (pH 8.0) 50 mM NaCl, 1 mM DTT, 5 mM MgCl2 and 5%
glycerol. The homogenate was divided into four aliquots and
DNase I was added (2, 4, 8 and 16 units per tube). Following
incubation at 15 1C for 5 min, the reaction was stopped by
addition of SDS to 1%, EDTA to 10 mM and Proteinase K to
100 μg/ml. After overnight incubation at 37 1C the DNA was
puriﬁed via phenol/chloroform extractions and ethanol precipita-
tion. Thereafter, the DNA was cleaved with KpnI/Bsu36I (hTERT A)
and BstEII/XmnI (hTERT B) in the presence of RNase A (30 μg/ml),
resolved in 1.5% agarose gel, vacuum transferred and hybridized
with [32P]-labeled probe. The probe was prepared by puriﬁcation
of the BglII/EcoRI digested fragment cleaved from hTERT
plasmid DNA.Results
Changes in histone H3K9 and H4K16 acetylation status
across the E-box region of the hTERT promoter upon
c-Myc/Max or Mnt/Max binding
In order to understand in more detail how c-Myc and Mnt
proteins regulate gene expression we have studied in vivo changes
in chromatin structure across the E-box region in the hTERT gene
reconstituted in Xenopus oocytes (Fig. S1A). First, DNA expression
vectors or in vitro synthesized mRNAs encoding c-Myc, Max or
Mnt were injected into the oocyte nuclei or cytoplasm, respec-
tively (Fig. S1A). The expression of the corresponding proteins
was detected either via 14C-Lysine incorporation followed by
detection by radio autography and/or phosphoimaging or by
Western blot analysis of the manually isolated oocyte nuclei or
whole oocytes (Fig. S1B–E). Next, we used electrophoretic mobi-
lity shift assay (EMSA) to show that exogenously expressed c-Myc
(Fig. S2A) and Mnt (Fig. S2B) form heterodimers with introduced
Max and that these complexes are able to bind speciﬁcally to the
E-box sequence (CACGTG) (Fig. S2A and B) in vitro. Interestingly,
when injecting mRNA encoding Max alone we identiﬁed a novel
Max-containing complex (X/Max, Fig. S2A), which may contain
Xenopus Myc [36], Mxd or Mnt proteins [37]. Due to the mobility
E X P E R I M E N T A L C E L L R E S E A R C H 3 1 9 ( 2 0 1 3 ) 3 1 6 0 – 3 1 6 9 3163of the band in the gel we reasoned that it most likely contained
Myc and to test this we used several different antibodies against
c-Myc and MYCN but none of them identiﬁed the protein
interacting with Max (data not shown). Thus Xenopus speciﬁc
antibodies would be needed to clarify the identity of this band.
Using chromatin immunoprecipitation (ChIP) assays we demon-
strated in vivo binding of c-Myc/Max and Mnt/Max to the 5′ and
the 3′ E-box in the hTERT promoter (Fig. 1A and B). We also
performed analysis of histone modiﬁcations across the E-boxFig. 1 – In vivo binding of exogenously expressed c-Myc/Max and M
(A) Overview of the hTERT A promoter construct showing the two E
in the ChIP assays. (B) Crosslinked chromatin from oocytes injecte
combination with 3 ng hTERT A promoter ssDNA was immunoprec
and H3K9ac. PCR primers covering the 5′ E-box or the 3′ E-box in
used. PCR ampliﬁcations of DNA from total chromatin were used a
independent experiments.region at the promoter co-occurring with c-Myc/Max or Mnt/Max
binding and found a characteristic pattern indicative of transcrip-
tional activation i.e. acetylation of H3K9 and H4K16 upon
c-Myc/Max binding. Importantly, acetylation of histone H3K9
and H4K16 was detected in oocytes injected with the hTERT
reporter alone but the levels were enhanced in oocytes expressing
c-Myc/Max, suggesting binding to already active chromatin. In
contrast, exogenous expression of Mnt/Max led to deacetylation of
histone H3K9 and H4K16 (Fig. 1B).nt/Max and histone acetylation status at the hTERT promoter.
-boxes and the hTERT E-box primers (indicated by arrows) used
d with 5.4 ng c-Myc, 0.7 ng Max or 3.1 ng Mnt mRNA in
ipitated with antibodies against c-Myc, Max, Mnt, IgG, H4K16ac
the hTERT promoter as well as control primers (vector) were
s input. The data shown are representative from two or three
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Mnt, respectively
In order to analyze the transcriptional response in oocytes
expressing c-Myc/Max and Mnt/Max we used luciferase reporter
assays (Fig. 2, Fig. S3A and B) and S1 nuclease protection analysis
(Fig. S3C). Three hTERT promoter constructs, containing different
lengths of the promoter fused to the luciferase gene were used
(Fig. 2A). A titration of the amount of injected c-Myc mRNA and
Mnt expression vector (Fig. S3B) revealed a 2–2.5 fold increase in
luciferase activity at the optimum concentration of c-Myc and
an almost complete transcriptional repression by Mnt/Max inXenopus oocytes (Fig. 2B). Similar results were observed in
HEK293T cells (Fig. 2C). In addition, we also analyzed the levels
of hTERT mRNA in the context of c-Myc/Max or Mnt/Max expres-
sion by S1 nuclease protection assay (Fig. S3C). By co-expression
with c-Myc/Max the levels of hTERT transcripts in the oocytes
increased with 1.5 fold whereas Mnt/Max expression repressed
the levels with 50% (Fig. S3C). Interestingly, co-injection of Myc
mRNA together with increasing amounts of Mnt DNA expression
vector resulted in transcriptional repression even though Mnt was
expressed at low levels (Fig. 2D). When the amount of Mnt
expression vector injected into the oocyte nucleus was diluted
down to 0.01 ng, the basal hTERT transcription was no longer
repressed and c-Myc/Max was able to activate transcription by
almost two-fold (Fig. 2D). Furthermore, we showed transcriptional
activation and repression of an artiﬁcial promoter (minM4tkLuc)
containing four E-boxes fused with the luciferase gene in oocytes
expressing introduced c-Myc and Mnt/Max, respectively (Fig. S3A
and B). Taken together, our data show that expression of c-Myc/
Max or Mnt/Max in the Xenopus oocyte model resulted in
activation and repression of hTERT driven transcription, respec-
tively, and that the balance between these two heterodimeric
complexes determines the transcriptional outcome.Sequence speciﬁc analysis of c-Myc/Max and Mnt/Max
binding to the hTERT promoter
To further characterize in vivo binding of c-Myc/Max and Mnt/
Max to the hTERT promoter we used dimethyl sulfate (DMS)
methylation protection assay [27]. This method allows detection
of sequence speciﬁc DNA-protein interactions in the living cell via
methylation at the N7 position of guanines in the major groove of
DNA. Methylated guanines are then converted to DNA strand
breaks [38], which are developed by 33P-labeled primer extension.
Thus, protein-DNA interactions are revealed as changes in DMS
reactivity caused by bound proteins, i.e. by protection from
methylation at these bases. Upon expression of c-Myc/Max we
observed two protected guanine residues located within the 3′
CACGTG palindrome. In addition, we observed an enhanced signalFig. 2 – Transcriptional response of the hTERT promoter
induced by expressed c-Myc/Max and Mnt/Max. (A) An
overview of the hTERT promoter constructs (hTERT A, B and C)
used in the Luciferase reporter assays. hTERT A and B are in the
pGL2-Enhancer vector and hTERT C in the pGL3-Basic vector, all
three containing the Luciferase reporter gene. (B-C) Luciferase
activity was measured after injection of 3 ng promoter
construct (hTERT A, hTERT B, hTERT C) alone or in combination
with 2.2 ng c-MycmRNA (hTERT A and B) or 4.3 ng c-MycmRNA
(hTERT C), 8 ng pRc-Mnt 1A DNA, and 2 ng pSp-Max DNA in
Xenopus oocytes (B) or 0.2 μg promoter construct (hTERT A,
hTERT B, hTERT C) alone or in combination with 1.2 μg pSp-
Myc or 1.2 μg pRc-Mnt 1A in HEK293T cells (C). (D) Luciferase
activity and protein expression were measured in oocytes
injected with a titration of pRc-Mnt 1A DNA (8, 4, 2, 1, 0.5, 0.1
and 0.01 ng), 2 ng pSp-Max, 3 ng c-Myc mRNA and 3 ng of the
hTERT B promoter construct. Relative luciferase activity was
presented as fold change in arbitrary units. Error bars indicate
standard deviations. Data shown are from two independent
experiments performed in triplicates.
Fig. 3 – Sequence speciﬁc analysis of c-Myc/Max or Mnt/Max binding. (A) and (B) Characterization of c-Myc/Max and Mnt/Max
binding by DMS methylation protection assay and primer extension of oocytes injected with 5.4/0.7 ng c-Myc/Max or 3.1/0.7 ng
Mnt/MaxmRNA in combination with 3 ng of the hTERT A promoter (A) or with 3 ng of minM4tkLuc construct (B). Naked hTERT (A)
or minM4tkLuc (B) DNA were used as controls (DNA ctrl). A schematic overview of the hTERT promoter construct used is shown to
left (A). The intensity of the bands was quantiﬁed by Fuji Bio-Imaging analyzer BAS-2500 using the Image Gauge V3.3 software and
shown as scans next to the gel. Methylation protection of the guanines in the 3′ hTERT E-box (A, upper right) and in the E-boxes of
the synthetic minM4tkLuc construct (B) are indicated with open circles. The hyper-methylated guanine positioned 1 bp
downstream of the 3′ E-box (A, lower right) and the hyper-methylated guanines downstream of the E-boxes in the synthetic
minM4tkluc construct (B) are indicated with closed circles. Methylation protection/hypermethylation of indicated bands was
quantiﬁed and related to the average of the reference bands (black triangles), setting the naked DNA to 100% methylation. The data
shown are representative from two independent experiments.
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of the consensus sequence (Fig. 3A, lanes 5, 6; scans to the left
and graphs to the right). This ﬁnding indicates increased protein
binding at the E-box, which is consistent with previous observa-
tions for other E-box containing genes [39]. Collectively, this
argues for speciﬁc c-Myc/Max binding to the 3′ E-box in the hTERT
promoter. However due to technical difﬁculties with the very GC-
rich sequence we were not able to visualize the binding pattern
across the 5′ E-box. Importantly, we noted that the methylation
protection pattern in oocytes injected with the hTERT promoter
together (Fig. 3A, lanes 5, 6) or without c-Myc/Max (Fig. 3A, lanes
3, 4) differed from that of naked DNA (Fig. 3A, lanes 1, 2) not only
in the region of the 3′ E-box but also in other places, thus
indicating binding at additional transcription factor sites (E2F, GC-
box and others) in the promoter (Fig. 3A).In contrast, E-box guanines were not protected from methylation
in oocytes expressing Mnt/Max (Fig. 3A, lanes 7, 8). Moreover, the
pattern of methylation protection pattern in these oocytes differed
substantially from the one generated in oocytes injected with the
hTERT DNA reporter alone (Fig. 3A, compare lanes 3, 4 and 7, 8) and
overall looked very similar to that of naked DNA used as control
(Fig. 3A, compare lanes 1, 2 and 7, 8). Together this suggests that Mnt/
Max binding (Fig. 1B) generates a chromatin structure, which is not
bound by other transcription factors. Thus, Mnt/Max mediates
transcriptional repression by complete chromatin condensation of
the hTERT core promoter, and thereby restricts the interaction of
other transcription factors with the DNA (Fig. 3A). This further
supports the notion of Mnt to act as a strong transcriptional
repressor. Interestingly, we observed methylation protection of all
four E-boxes in the artiﬁcial minM4tkLuc promoter in oocytes
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lane 6, 7) thus suggesting that Mnt is not repressing the minM4tkLuc
chromatin in the same manner as it does at the hTERT promoter.
c-Myc/Max binding induces an open chromatin structure
within the E-box region
Next, we addressed the DNA accessibility of the chromatin across the
E-box region at the hTERT promoter in oocytes expressing c-Myc/Fig. 4 – Increased DNA accessibility in the E-box region of the hTE
oocytes injected with 3 ng c-Myc or 8 ng Mnt and 2 ng Max DNA t
increasing concentrations of DNase I and hypersensitive sites were
promoter DNA digested with Kpn I and partially with Pml I (Pml I/K
Quantiﬁcations of the bands are shown in the scans to the right. T
corresponding to undigested DNA. Data are representative from th
measured in extracts from the pool of oocytes used for DNase I diMax or Mnt/Max by DNase I hypersensitivity assay. DNase I rapidly
digests open chromatin regions, and thereby identiﬁes sites where
chromatin remodeling takes place. Upon injection of the hTERT A or B
reporter alone, DNase I hypersensitivity was observed just down
stream of the 5′ E-box as well as in the area between the two
E-boxes (Fig. 4A, lane 1–4; and data not shown). Expression of
c-Myc/Max resulted in enhanced DNA accessibility of this region
(Fig. 4A, lane 5–8; and data not shown) compared to oocytes
expressing the hTERT reporter alone (Fig. 4A, lane 1–4; and dataRT promoter upon c-Myc/Max binding. (A) DNA from Xenopus
ogether with 3 ng hTERT B promoter DNA was digested with
identiﬁed by Southern Blot and indirect end-labeling. hTERT
pn I ctrl) was used to localize the E-boxes within the promoter.
he scans were adjusted according to the intensity of the band
ree independent experiments. (B) Luciferase activity was
gestion and presented as fold change.
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observed down stream of the 3′ E-box (Fig. 4A, lanes 5–8; and data
not shown), thus suggesting a more open chromatin structure in this
area upon c-Myc/Max binding. Importantly, the E-box region was
still sensitive to DNase I action when the Mnt/Max complex was
exogenously expressed (Fig. 4A, lane 9–12; and data not shown).
However the overall DNase I hypersensitivity was lower compared
to when the hTERT promoter was injected alone (Fig. 4A, lane 1–4)
or when the hTERT was bound by c-Myc/Max (Fig. 4A, lane 5–8).
Taken together, these results suggested that chromatin remodeling
events took place in the area down stream of as well as between the
two E-boxes in the hTERT promoter upon c-Myc/Max and Mnt/Max
binding.Discussion
The Myc oncoproteins are deregulated in the majority of human
cancers [1]. It has been shown that Myc/Max heterodimers
interact with 10–15% of human promoters and target already
active or potentially active, i.e. preset, chromatin by binding
preferentially to promoters carrying histone H3K9 and H3K18
acetylation marks as well as di- and tri-methylations of H3K4 and
di-methylation of H3K79 [3–8]. In this study, we have used the
Xenopus oocyte model, which allows in vivo chromatin and
transcriptional studies of a reconstituted promoter at high preci-
sion. As c-Myc has been suggested to be important for regulating
hTERT transcription during immortalization [32,40–43] we
wanted to investigate how c-Myc regulates gene expression at
the level of chromatin remodeling. We showed c-Myc/Max
binding to both E-boxes in the hTERT promoter, which were
already enriched for acetylated histones H3K9 and H4K16. How-
ever, the basal levels of H3K9 and H4K16 acetylation observed in
the oocytes injected with the hTERT reporter alone might be due
to binding of endogenous Xenpous Myc. In addition, we observed
a modest 2–2.5 fold activation of hTERT transcription by ectopi-
cally expressed c-Myc (Fig. 2, S3), which supports the role of Myc
in ﬁne-tuning of gene expression. This could be due to recruit-
ment of histone modifying complexes since we showed increased
levels of H3K9ac and H4K16ac (Fig. 1B) upon c-Myc/Max binding.
These factors in turn locally hyperacetylate histones resulting in
disruption of the interaction between neighboring nucleosomes
and, thus, opens the chromatin ﬁber [10,13,44–46]. In support, we
demonstrated increased DNA accessibility between the E-boxes
and at both the 5′ and 3′ E-boxes upon c-Myc/Max binding
arguing for formation of a more open chromatin structure
(Fig. 4A). The appearance of a major DNase I hypersensitive site
located near the transcription start site in the promoter has
previously been shown upon transcriptional activation [46]. This
site may correspond to the DNase I hypersensitive site that we
identiﬁed close to the 3′ E-box (Fig. 4A). In addition, Wang et al.,
showed that the nucleosomal organization of the hTERT promoter
was changed upon differentiation of proliferating HL60 cells.
These authors showed that the nucleosomal-free regions, which
were present in the core promoter in proliferating cells, disap-
peared when cells were induced to differentiate and transcription
was repressed [47]. Our data, showing differences in DNase I
hypersensitivity as well as in the levels of histone acetylation
across the E-boxes suggests differences in nucleosomal organiza-
tion upon c-Myc/Max or Mnt/Max binding, respectively.The hTERT gene is repressed in human somatic cells but reacti-
vated upon immortalization (reviewed in [48]). This has been shown
to be possible by for example inhibition of HDACs [24,46,49]. Here,
we demonstrate that Mnt induces de-acetylation of histone H3K9
and H4K16 across the entire E-box region (Fig. 1B) and represses
transcription of the hTERT promoter upon binding to both E-boxes
(Fig. 1B, Fig. 2S3). Our data suggests Mnt to act as a strong
transcriptional repressor since it inhibited c-Myc-induced transcrip-
tional activation even when expressed at low levels. In addition,
Mnt/Max completely repressed hTERT transcription induced by
endogenous factors (Fig. 2). We also showed that Mnt/Max binding
resulted in complete condensation of the hTERT core promoter
chromatin (Fig. 3A). In contrast, we observed methylation protection
of the guanines in all four E-boxes in the minM4tkLuc construct
upon Mnt/Max binding (Fig. 3B). This suggests that Mnt does not
compact the chromatin structure of the artiﬁcial promoter in the
same manner as it does with the hTERT promoter. Speciﬁc chromatin
folding characteristic for the artiﬁcial promoter and/or lack of
binding partners/co-repressors, which are present in the hTERT
promoter could be possible explanations. The fact that binding of
Mnt/Max caused DNase I hypersensitivity in the E-box region
(Fig. 4A), suggest a similar mechanism of gene silencing as has been
reported for the Groucho (Gro/TLE/Grg) co-repressors [50]. Recruit-
ment of Groucho by transcription factors was found to cause higher
order condensed complexes of polynucleosome arrays, which sur-
prisingly are in an open, exposed conﬁguration accessible to DNase I
action [50]. Thus, we suggest that Mnt/Max might repress transcrip-
tion in a similar manner.
Taken together, our data show that c-Myc/Max binds to open/
active chromatin region and contributes to the ﬁne-tuning of gene
expression by inducing local hyperacetylation of histone H3K9
and H4K16 and increased DNA accessibility of the hTERT core
promoter. In contrast, Mnt/Max binding deacetylates H3K9 and
H4K16, and represses transcription by complete condensation of
the chromatin structure across the E-box region within the hTERT
promoter. Thus, our ﬁndings strengthen the role of Mnt as a key
regulator of the Myc/Max/Mxd/Mnt network.Acknowledgments
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